Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Name: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
Published: 2026
License: Public Domain

French Innovative Leukemia Organisation · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia, acute myeloid leukemia and idh1 mutation, complete remission after intensive chemotherapy, ivosidenib and oral azacitidine, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Related documents